For decades, only two nitroheterocyclic drugs have been used as therapeutic agents for
Chagas disease. However, these drugs present limited effectiveness during the chronic …

For decades, only two nitroheterocyclic drugs have been used as therapeutic agents for
Chagas disease. However, these drugs present limited effectiveness during the chronic …

Chagas disease (CD) is a human infection caused by Trypanosoma cruzi. CD was
traditionally endemic to the Americas; however, due to migration it has spread to countries …

Chagas disease is an illness caused by the protozoan parasite Trypanosoma cruzi. The
current chemotherapy is based on benznidazole, and, in some countries, Nifurtimox, which …

Chagas disease is a parasitic infection caused by protozoan Trypanosoma cruzi that affects
approximately 6–7 million people worldwide. Benznidazole is the only drug approved for …

Pharmacological treatment of Chagas disease is based on benznidazole, which displays
poor efficacy when administered during the chronic phase of infection. Therefore, the …

Chagas disease, caused by Trypanosoma cruzi, is a widespread infection in Latin America.
Currently, only 2 partially effective and highly toxic drugs, ie, benznidazole and nifurtimox …

Current treatments for Chagas disease have a limited impact during the chronic stage and
trigger severe side effects. Treatments target Trypanosoma cruzi, the etiological agent of the …

Chagas disease is present in Latin America, North America, Europe, and Asia, where
between 6 and 7 million people are infected. This illness is transmitted mainly by the insect …

To develop novel chemotherapeutic alternatives for the treatment of Chagas disease, in this
study, a set of new amino naphthoquinone derivatives were synthesised and evaluated in …